Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease
2016 (English)In: Nature Communications, ISSN 2041-1723, E-ISSN 2041-1723, Vol. 7, 10759Article in journal (Refereed) PublishedText
Owing to their specificity and high-affinity binding, monoclonal antibodies have potential as positron emission tomography (PET) radioligands and are currently used to image various targets in peripheral organs. However, in the central nervous system, antibody uptake is limited by the blood-brain barrier (BBB). Here we present a PET ligand to be used for diagnosis and evaluation of treatment effects in Alzheimer's disease. The amyloid beta (A beta) antibody mAb158 is radiolabelled and conjugated to a transferrin receptor antibody to enable receptor-mediated transcytosis across the BBB. PET imaging of two different mouse models with Ab pathology clearly visualize A beta in the brain. The PET signal increases with age and correlates closely with brain A beta levels. Thus, we demonstrate that antibody-based PET ligands can be successfully used for brain imaging.
Place, publisher, year, edition, pages
2016. Vol. 7, 10759
Geriatrics Radiology, Nuclear Medicine and Medical Imaging
IdentifiersURN: urn:nbn:se:uu:diva-282384DOI: 10.1038/ncomms10759ISI: 000371037200021PubMedID: 26892305OAI: oai:DiVA.org:uu-282384DiVA: diva2:917054
FunderSwedish Research Council, 2012-1593Swedish Research Council, 2012-2172The Swedish Brain Foundation